When CRISPR-Cas9 gene editing technology was first commercialized, which pricing strategy did the leading suppliers primarily adopt?

In the competitive world of scientific product development, pricing strategies for breakthrough molecular technologies can make or break market adoption. This poll tests your knowledge of how a revolutionary gene-editing technology was initially priced to balance accessibility for research institutions while maintaining profitability. Understanding pricing models for scientific innovations reveals the delicate balance between scientific advancement and commercial viability.

This is a live public trivia poll on AIPolls.Net. Vote and see real-time results.

Tiered licensing model with different rates for academic vs. commercial use
Subscription-based access with unlimited edits for a monthly fee
One-time purchase with high upfront cost and no ongoing fees
Pay-per-edit model with costs scaling based on complexity of genetic modifications